Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Johnson & Johnson (JNJ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 367,316,128
  • Shares Outstanding, K 2,682,902
  • Annual Sales, $ 81,581 M
  • Annual Income, $ 15,297 M
  • 60-Month Beta 0.68
  • Price/Sales 4.54
  • Price/Cash Flow 12.67
  • Price/Book 6.20

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate 2.07
  • Number of Estimates 8
  • High Estimate 2.15
  • Low Estimate 1.96
  • Prior Year 2.06
  • Growth Rate Est. (year over year) +0.49%

Price Performance

See More
Period Period Low Period High Performance
1-Month
135.39 +1.12%
on 02/27/19
140.00 -2.21%
on 03/12/19
+0.31 (+0.23%)
since 02/22/19
3-Month
121.00 +13.15%
on 12/24/18
140.00 -2.21%
on 03/12/19
+8.82 (+6.89%)
since 12/21/18
52-Week
118.62 +15.42%
on 05/29/18
148.99 -8.11%
on 12/04/18
+9.53 (+7.48%)
since 03/22/18

Most Recent Stories

More News
Janssen Seeks Expanded Use of DARZALEX(R) (daratumumab) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a Type II variation application to the European Medicines Agency (EMA) for DARZALEX(R) (daratumumab)...

JNJ : 136.91 (-0.86%)
Cooper Companies' (COO) CooperVision Gains Momentum Globally

Cooper Companies (COO) maintains its leading position in the markets of specialty lenses, supported by highly exclusive products like Biofinity and Clariti.

EYE : 29.07 (-2.29%)
COO : 291.76 (-1.85%)
JNJ : 136.91 (-0.86%)
NVS : 93.42 (-0.26%)
Alkermes Focuses on Pipeline, Depends on Partners for Funds

Alkermes (ALKS) has an impressive pipeline and is focused on the development of its candidates.

JNJ : 136.91 (-0.86%)
LLY : 128.30 (-0.01%)
ALKS : 33.96 (-2.80%)
BIIB : 216.71 (-4.48%)
Asian shares gain as Fed says it will hold off on rate hikes

BANGKOK (AP) — Shares in Asia were mostly higher on Thursday after the Federal Reserve said it has ruled out interest rate increases for this year.

MSFT : 117.05 (-2.64%)
GIS : 50.74 (+1.40%)
GOOGL : 1,207.65 (-2.30%)
CI : 166.09 (-1.65%)
JNJ : 136.91 (-0.86%)
FDX : 173.99 (-2.79%)
UNH : 247.09 (-1.96%)
KEY : 14.97 (-6.09%)
FedEx, Johnson and Johnson slump while General Mills rises

NEW YORK (AP) — Stocks that moved substantially or traded heavily on Wednesday:

SCS : 14.77 (-3.46%)
JNJ : 136.91 (-0.86%)
AIR : 32.59 (-3.32%)
FDX : 173.99 (-2.79%)
SMAR : 41.62 (-8.85%)
VIA : 30.85 (-1.66%)
Markets Right Now: Fed news sends bond yields sharply lower

NEW YORK (AP) — The latest on developments in financial markets (all times local):

JNJ : 136.91 (-0.86%)
VIA : 30.85 (-1.66%)
AbbVie's Venclexta Multiple Myeloma Studies Put on Hold by FDA

FDA places a partial clinical hold on all studies evaluating AbbVie's (ABBV) Venclexta (venetoclax) for the treatment of multiple myeloma.

JNJ : 136.91 (-0.86%)
ABBV : 79.76 (-1.82%)
TEVA : 16.33 (-4.39%)
RHHBY : 33.7600 (-1.06%)
Next Support Level for Johnson&Johnson (JNJ) is $136.83

Shares of Johnson&Johnson (NYSE:JNJ) have bearishly opened below the pivot of $138.14 today and have reached the first support level of $137.47. Should the shares continue to fall, the support pivots...

JNJ : 136.91 (-0.86%)
Adopt The Growth Mindset To Kickstart Your Success

DALLAS, TX / ACCESSWIRE / March 19, 2019 / Major Depressive Disorder on average affects over 16.1 million adults over the age of 18. If you are someone who feels lost, alone, or aimless, chances are the...

JNJ : 136.91 (-0.86%)
Johnson & Johnson to Host Investor Conference Call on First-Quarter Results

Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 16th, to review first-quarter results. Joseph J. Wolk, Executive Vice President, Chief...

JNJ : 136.91 (-0.86%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Falling.

See More Share

Trade JNJ with:

Business Summary

Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin...

See More

Key Turning Points

2nd Resistance Point 138.92
1st Resistance Point 137.91
Last Price 136.91
1st Support Level 136.38
2nd Support Level 135.86

See More

52-Week High 148.99
Fibonacci 61.8% 137.39
Last Price 136.91
Fibonacci 50% 133.81
Fibonacci 38.2% 130.22
52-Week Low 118.62

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar